Výsledky vyhledávání - "Massacese, S."

Akademický článek

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

Autor: Bruera G; Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Massacese S; Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Pepe F; Department of Public Health, University Federico II, Napoli, Italy., Malapelle U; Department of Public Health, University Federico II, Napoli, Italy., Dal Mas A; Pathology, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Ciacco E; Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Calvisi G; Pathology, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Troncone G; Department of Public Health, University Federico II, Napoli, Italy., Simmaco M; Advanced Molecular Diagnostics, S. Andrea Hospital, Rome, Italy., Ricevuto E; U.O.S.D. Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, L'Aquila 67100, Italy.

Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2019 May 10; Vol. 11, pp. 1758835919846421. Date of Electronic Publication: 2019 May 10 (Print Publication: 2019).

Zobrazit plný text záznamu

Akademický článek

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study.

Autor: Bruera G; Oncology Territorial Care Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Massacese S; Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Candria S; Oncology Territorial Care Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy., Galvano A; Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy., Manetta R; Radiology Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Giordano AV; Radiology Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Carducci S; Radiology Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Di Sibio A; Radiology Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Ciacco E; Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Russo A; Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy., Ricevuto E; Oncology Territorial Care Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Publikováno v: Oncotarget [Oncotarget] 2018 Aug 07; Vol. 9 (61), pp. 31861-31876. Date of Electronic Publication: 2018 Aug 07 (Print Publication: 2018).

Zobrazit plný text záznamu

Akademický článek

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer.

Autor: Bruera G; Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Massacese S; Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Galvano A; Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy., Mas AD; Pathology, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Guadagni S; University General Surgery, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Calvisi G; Pathology, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Ciacco E; Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy., Russo A; Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy., Ricevuto E; Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Publikováno v: Oncotarget [Oncotarget] 2018 Apr 17; Vol. 9 (29), pp. 20339-20350. Date of Electronic Publication: 2018 Apr 17 (Print Publication: 2018).

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání